|
8-Aug-2022
Investor presentation, 8 August 2022
Investor presentation, 8 August 2022
|
8-Aug-2022
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
|
29-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report
Quarterly Activities/Appendix 4C Cash Flow Report
|
19-Jul-2022
Acadia submits Rett Syndrome New Drug Application to the FDA
Acadia submits Rett Syndrome New Drug Application to the FDA
|
12-Jul-2022
Neuren commences Phase 2 trial of NNZ-2591 in Angelman syndrome
Neuren commences Phase 2 trial of NNZ-2591 in Angelman syndrome
|
8-Jul-2022
Notification regarding unquoted securities - NEU
Notification regarding unquoted securities - NEU
|
8-Jul-2022
Neuren appoints Chief Medical Officer in United States
Neuren appoints Chief Medical Officer in United States
|
30-May-2022
Results of Meeting
Results of Meeting
|
30-May-2022
AGM Chairman's Address & CEO Presentation
AGM Chairman's Address & CEO Presentation
|
29-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report
Quarterly Activities/Appendix 4C Cash Flow Report
|